Ardigen and Selvita Now Offer Joint Cell Painting Services

Topic:

Ardigen, a world-renowned leader in artificial intelligence and precision medicine, announces a partnership with Selvita for cell painting services. This collaboration aims to leverage Ardigen’s expertise in AI and Selvita’s proficiency to advance innovative solutions in the area of precision medicine.

The Methodology of Jointed Cell Painting Services

Using fluorescent labels, the advanced technology will enable laboratory professionals to perform detailed analysis of cell morphology. Then, the Ardigen phenAId platform will be used to interpret high-content data from the process.

Then, phenAId executes image analysis to identify patterns and morphological profiling. Its multi-modal properties allow researchers to undertake several tasks:

  1. Predicting Mode of Action – to optimize the development process for faster results indicative of a drug candidate;
  2. Predicting Off-Target Effect – to reduce costs associated with drug withdrawals due to side effects;
  3. Predicting Biological Activity – to improve compound collections and adding new samples to libraries.
  4. Hit Identification –  to find new starting points for drug candidates;
  5. Virtual Screening – to discover new drug candidates or find new uses for existing drugs.

All results are presented in a comprehensive, automated report. 

You can see the detailed offer at Selvita’s website here: https://selvita.com/drug-discovery/assay-development-screening/cell-painting-service/

About Selvita:

Selvita stands as one of Europe’s largest preclinical contract research organizations. With a focused mission of bridging the gap between early drug discovery and clinical development, Selvita consists of a team of over 900 experts across six sites in Europe and the U.S. It provides high-quality, comprehensive drug discovery and development services across diverse therapeutic areas.

Expert Contribution

Reviewed by: Dr. Maciej Jasiński, PhD
Role: Director of Biologics, AI‑Driven Drug Discovery
Expertise: AI-driven biologics discovery, machine learning, structural bioinformatics, computational biology, peptide and protein binder design, HLA peptide prediction, cross-functional team leadership

You might be also interested in:

Blog cover for Ardigen publication on ARDisplay-I and MHC ligand identification in Molecular & Cellular Proteomics
New publication in MCP: Improving MHC ligand identification with machine learning and optimized isolation
Fluorescence microscopy image of cells stained with multiple Cell Painting dyes showing cellular organelles in green, blue, and pink, overlaid with Ardigen brand graphic elements indicating phenomics data in durg discovery
End to End Data-to-Decision Journey for AI-Driven Phenomics in Drug Discovery
Abstract network visualization representing AI-driven integration of biological data and knowledge graphs for target identification in drug discovery.
Target Identification: From Poor Data to Quality Predictions
Abstract data streams representing data sourcing in pharmaceutical research and AI drug discovery
What Are Common Data Sourcing Patterns in Pharmaceutical Research (part 3)

Contact

Ready to transform drug discovery?

Discover how one of the top AI CROs in the world, can be your trusted partner in revolutionizing drug discovery through AI.

Contact us today to learn more about our tailored solutions for empowering your drug development journey.

Send us a message and we will contact you back within 48 hours.

Newsletter

Become an insider

Be the first to know about Ardigen’s latest news and get access to our publications, webinars and more!